LIGAND PHARMACEUTICALS (Nasdaq: LGND) Total Insider buying: $8,930,108.56
There are 13 upcoming Trade Catalysts listed in our calendar including one upcoming Full Phase II trial result for Captisol-Enabled melphalan hydrochloride as indicated for Multiple Myeloma.
Ligands Captisol-enabled melphalan program has been granted Orphan Drug status by the FDA as a conditioning treatment for use in autologous transplant for patients with multiple myeloma. This new IV formulation of melphalan (currently sold as Alkeran for Injection) has the potential to offer multiple advantages for clinicians and patients in the multiple myeloma transplant setting.
Ligand engages in the research, milestone, and royalty revenue activities resulting from its collaborations with pharmaceutical partners. The collaborations primarily include ongoing clinical programs at Bristol-Myers Squibb (BMY), GlaxoSmithKline (GSK), Pfizer (PFE), Merck & Co. (MRK), Cephalon, Inc (CEPH), and Celgene (CELG). These partnered product candidates are being studied for the treatment of indications such as thrombocytopenia, rheumatoid arthritis, chronic obstructive pulmonary disease, asthma, osteoporosis, menopausal symptoms, and Alzheimer’s disease.
Market Data 
Markets 
AI
